Pharmacist Perspectives on the Arrival of Subcutaneous Immune Checkpoint Inhibitors in the Cancer Therapy Armamentarium
Tracking # 20-1314808
Free
There are no ratings for this course
Learn moreCourse overview
The goal of this educational activity is to equip oncology, specialty, and managed care pharmacists with the knowledge, confidence, competence, and practical tools necessary to lead the safe, effective, evidence-based, and patient-centric integration of subcutaneous ICIs into the evolving cancer care paradigm.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
Dr. Baek has no relevant affiliations or financial relationships with a commercial interest to disclose.
The clinical reviewer, Megan May, PharmD, BCOP has disclosed that she receives non-CME honoraria from Amgen and Astra Zeneca.
Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.